Excellence in Research & Development
“I think this award will go a long way in making sure we continue our efforts towards R&D and help us accomplish greater heights, not just in India, but on a global scale”
– Glenn Saldanha Managing Director and Chief Executive Officer
It’s been twice in a row that Glenmark Pharmaceutical has won the Excellence in R&D award. “At Glenmark we have set ourselves a vision and a direction to try and strive hard to make sure we move the first molecule that comes out of India into the market, which is indigenously produced,” said Glenn Saldanha, Managing Director and Chief Executive Officer, Glenmark Pharmaceuticals, as he accepted the award from the Honourable Union Minister of Science and Development and Earth Sciences, Kapil Sibal. “I think this award will go a long way in making sure we continue our efforts towards R&D and help us accomplish greater heights, not just in India, but on a global scale,” he added.
The sole purpose of this award is to credit companies that have a definitive and result-oriented R&D agenda, and who have been able to carve a niche for themselves in this segment in the industry. Express Pharma, Ernst & Young and the jury panel observed Glenmark as the most favourable candidate for this category. Glenmark has many products and patents gracing its pipeline. A novel CB2 modulator for treatment of pain, neurogenerative disorder, inflammatory diseases, a novel CB1 modulator for treatment of obesity, eating disorders, inflammatory diseases and a new novel VR1 receptor ligands for treatment of pain are just a few feathers gracing the company’s cap. Glenmark is also working on two new drug delivery systems. One is a topical pharmaceutical composition on anti-acne compound and the other is a topical pharmaceutical combination comprising an antibiotic and retinoid like compound. The patent filings for both have been accepted.
Another candidate under development is the polymorphic form of active API, polymorphic form of lercanidipine and the process for the preparation thereof. The benefits of this include neo-polymorphic form of lercamidipin hydrochloride, useful as an anti-hypertensive calcium channel blocker. Apart from these, the company is involved in two drug patent challenges over Desloratadine and Ezetimibe.
|Dr Reddy’s Laboratories
Dr Reddy’s Laboratories has an approved patent for thiazoles derivatives as an AMPK activator, which is used for the treatment of diabetes. The patent application for the novel class of anti-bacterial compounds for the treatment of infectious diseases and formulation used in Phase III clinical trials was also accepted.
As one of the few research based companies in the country, Ranbaxy has much to boast of, especially, the key NCE patent filed by the company for substituted pyrrole derivatives of the statin class of compounds. This compound is indicated for the treatment of hypertension, stroke, ischemia, coronary heart diseases, myocardial infarction, cerebral infarction, dementia, angina or restenosis.